What This Means
This research suggests that the aging process itself — not just genetic mutations — plays a major role in why older men are more likely to develop prostate cancer and why the disease can be harder to treat. As cells in the prostate age, some enter a state called 'senescence,' where they stop dividing but release a toxic mix of inflammatory signals (known as SASP) into the surrounding tissue. Over time, this creates a smoldering, low-grade inflammatory environment throughout the body and specifically in the prostate, a process the authors call 'inflammaging.' This aged, inflamed environment appears to make it easier for cancer to start, grow, spread, and resist treatment.
The review also highlights how the aging immune system loses its ability to detect and destroy cancer cells. Specific immune cell types — including T-cells, macrophages, and myeloid cells — become imbalanced or dysfunctional with age, reducing the body's natural cancer surveillance. Inflammatory signaling pathways (particularly involving molecules called IL-17 and IL-23) become dysregulated, further tilting the microenvironment in favor of tumor growth. The aging of supportive tissue (stroma) and metabolic changes in aging cells add additional layers of complexity to how the prostate environment becomes cancer-permissive.
This research suggests that future prostate cancer treatments may benefit from directly targeting the biology of aging — for example, by neutralizing SASP signals, eliminating senescent cells, correcting immune imbalances, or addressing metabolic dysfunction in aged tissue. The authors call for an 'age-aware' approach to prostate cancer research, emphasizing the need to develop biomarkers that reflect aging biology and to design clinical strategies that account for a patient's aging microenvironment, not just the tumor's genetic profile.